IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus - Trial NCT01841619
Access comprehensive clinical trial information for NCT01841619 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by University of California, Irvine and is currently Completed. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 16 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of California, Irvine
Timeline & Enrollment
Early Phase 1
Mar 01, 2013
Nov 01, 2014
Primary Outcome
Cutaneous Lupus Erythematosus Disease Area and Severity Index - Total Activity Score (CLASI - TAS),Skindex 29
Summary
The purpose of this research study is to show that non-steroidal treatment with intravenous
 immunoglobulin (IVIg) can replace current systemic immunosuppressive therapy in cutaneous
 lupus erythematosis (CLE) patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01841619
Non-Device Trial